Search

Your search keyword '"Gonzalez-Gay, M. A."' showing total 425 results
Start Over Author "Gonzalez-Gay, M. A."
425 results on '"Gonzalez-Gay, M. A."'

1. AB1313 18F-FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY FINDINGS OF POLYMYALGIA RHEUMATICA IN PATIENTS WITH LARGE VESSEL VASCULITIS

Author

Heras-Recuero, E., primary, Martínez de Bourio-Allona, M., additional, Landaeta-Kancev, L. C., additional, Blázquez-Sánchez, T., additional, Torres-Roselló, A., additional, Álvarez-Rubio, M., additional, Belhaj-Gandar, M., additional, Martínez-Dhier, L., additional, Martinez-Lopez, J. A., additional, Largo, R., additional, and Gonzalez-Gay, M. A., additional

Published
2024
Full Text
View/download PDF

2. Defining anti-synthetase syndrome: a systematic literature review

Author

Zanframundo, G, Faghihi-Kashani, S, Scire, C, Bonella, F, Corte, T, Doyle, T, Fiorentino, D, Gonzalez-Gay, M, Hudson, M, Kuwana, M, Lundberg, I, Mammen, A, Mchugh, N, Miller, F, Monteccucco, C, Oddis, C, Rojas-Serrano, J, Schmidt, J, Selva-O'Callaghan, A, Werth, V, Sakellariou, G, Aggarwal, R, Cavagna, L, Zanframundo G., Faghihi-Kashani S., Scire C. A., Bonella F., Corte T. J., Doyle T. J., Fiorentino D., Gonzalez-Gay M. A., Hudson M., Kuwana M., Lundberg I. E., Mammen A., McHugh N., Miller F. W., Monteccucco C., Oddis C. V., Rojas-Serrano J., Schmidt J., Selva-O'Callaghan A., Werth V. P., Sakellariou G., Aggarwal R., Cavagna L., Zanframundo, G, Faghihi-Kashani, S, Scire, C, Bonella, F, Corte, T, Doyle, T, Fiorentino, D, Gonzalez-Gay, M, Hudson, M, Kuwana, M, Lundberg, I, Mammen, A, Mchugh, N, Miller, F, Monteccucco, C, Oddis, C, Rojas-Serrano, J, Schmidt, J, Selva-O'Callaghan, A, Werth, V, Sakellariou, G, Aggarwal, R, Cavagna, L, Zanframundo G., Faghihi-Kashani S., Scire C. A., Bonella F., Corte T. J., Doyle T. J., Fiorentino D., Gonzalez-Gay M. A., Hudson M., Kuwana M., Lundberg I. E., Mammen A., McHugh N., Miller F. W., Monteccucco C., Oddis C. V., Rojas-Serrano J., Schmidt J., Selva-O'Callaghan A., Werth V. P., Sakellariou G., Aggarwal R., and Cavagna L.

Abstract

Anti-synthetase syndrome (ASSD) is a heterogeneous autoimmune disease characterised by multi-system involvement with a wide variety of manifestations. Validated classification criteria are necessary to improve recognition and prevent misclassification, especially given the lack of reliable and standardised autoantibody testing. We systematically reviewed the literature to analyse proposed ASSD criteria, characteristics, and diagnostic performance. Methods We searched PubMed and Embase databases (01/01/1984 to 06/11/2018) and the ACR and EULAR meeting abstracts (2017-2018). Sensitivities, specificities, positive, negative likelihood ratios and risk of bias were calculated for ASSD criteria and key variables reported in the literature. We performed meta-analysis when appropriate. Results We retrieved 4,358 studies. We found 85 proposed ASSD criteria from a total of 82 studies. All but one study included anti-synthetase autoantibody (ARS) positivity in the ASSD criteria. Most studies required only one ASSD feature plus anti-ARS to define ASSD (n=64, 78%), whereas 16 studies required more than one ASSD variable plus anti-ARS. The only criteria not including anti-ARS positivity required 5 ASSD clinical features. We found limited data and wide variability in the diagnostic performance of each variable and definition proposed in the literature. Given these limitations we only meta-analysed the performance of individual muscle biopsy and clinical variables in diagnosing ASSD, which performed poorly. Conclusion The current ASSD criteria include a variety of serological, clinical, and histological features with wide variability amongst proposed definitions and the performance of these definitions has not been tested. This systematic literature review suggests the need for additional data and consensus-driven classification criteria for ASSD.

Published
2022

3. Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies

Author

Cavagna, L, Meloni, F, Meyer, A, Sambataro, G, Belliato, M, De Langhe, E, Cavazzana, I, Pipitone, N, Triantafyllias, K, Mosca, M, Barsotti, S, Zampogna, G, Biglia, A, Emmi, G, De Visser, M, Van Der Kooi, A, Parronchi, P, Hirschi, S, da Silva, J, Scire, C, Furini, F, Giannini, M, Martinez Gonzalez, O, Damian, L, Piette, Y, Smith, V, Mera-Valera, A, Bachiller-Corral, J, Cabezas Rodriguez, I, Brandy-Garcia, A, Maurier, F, Perrin, J, Gonzalez-Moreno, J, Drott, U, Delbruck, C, Schwarting, A, Arrigoni, E, Sebastiani, G, Iuliano, A, Nannini, C, Quartuccio, L, Rodriguez Cambron, A, Blazquez Canamero, M, Villa Blanco, I, Cagnotto, G, Pesci, A, Luppi, F, Dei, G, Romero Bueno, F, Franceschini, F, Chiapparoli, I, Zanframundo, G, Lettieri, S, De Stefano, L, Cutolo, M, Mathieu, A, Piga, M, Prieto-Gonzalez, S, Moraes-Fontes, M, Fonseca, J, Jovani, V, Riccieri, V, Santaniello, A, Montfort, S, Bilocca, D, Erre, G, Bartoloni, E, Gerli, R, Monti, M, Lorenz, H, Sambataro, D, Bellando Randone, S, Schneider, U, Valenzuela, C, Lopez-Mejias, R, Cifrian, J, Mejia, M, Gonzalez Perez, M, Wendel, S, Fornaro, M, De Luca, G, Orsolini, G, Rossini, M, Dieude, P, Knitza, J, Castaneda, S, Voll, R, Rojas-Serrano, J, Valentini, A, Vancheri, C, Matucci-Cerinic, M, Feist, E, Codullo, V, Iannone, F, Distler, J, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Meloni F., Meyer A., Sambataro G., Belliato M., De Langhe E., Cavazzana I., Pipitone N., Triantafyllias K., Mosca M., Barsotti S., Zampogna G., Biglia A., Emmi G., De Visser M., Van Der Kooi A., Parronchi P., Hirschi S., da Silva J. A. P., Scire C. A., Furini F., Giannini M., Martinez Gonzalez O., Damian L., Piette Y., Smith V., Mera-Valera A., Bachiller-Corral J., Cabezas Rodriguez I., Brandy-Garcia A. M., Maurier F., Perrin J., Gonzalez-Moreno J., Drott U., Delbruck C., Schwarting A., Arrigoni E., Sebastiani G. D., Iuliano A., Nannini C., Quartuccio L., Rodriguez Cambron A. B., Blazquez Canamero M. A., Villa Blanco I., Cagnotto G., Pesci A., Luppi F., Dei G., Romero Bueno F. I., Franceschini F., Chiapparoli I., Zanframundo G., Lettieri S., De Stefano L., Cutolo M., Mathieu A., Piga M., Prieto-Gonzalez S., Moraes-Fontes M. F., Fonseca J. E., Jovani V., Riccieri V., Santaniello A., Montfort S., Bilocca D., Erre G. L., Bartoloni E., Gerli R., Monti M. C., Lorenz H. M., Sambataro D., Bellando Randone S., Schneider U., Valenzuela C., Lopez-Mejias R., Cifrian J., Mejia M., Gonzalez Perez M. -I., Wendel S., Fornaro M., De Luca G., Orsolini G., Rossini M., Dieude P., Knitza J., Castaneda S., Voll R. E., Rojas-Serrano J., Valentini A., Vancheri C., Matucci-Cerinic M., Feist E., Codullo V., Iannone F., Distler J. H., Montecucco C., Gonzalez-Gay M. A., Cavagna, L, Meloni, F, Meyer, A, Sambataro, G, Belliato, M, De Langhe, E, Cavazzana, I, Pipitone, N, Triantafyllias, K, Mosca, M, Barsotti, S, Zampogna, G, Biglia, A, Emmi, G, De Visser, M, Van Der Kooi, A, Parronchi, P, Hirschi, S, da Silva, J, Scire, C, Furini, F, Giannini, M, Martinez Gonzalez, O, Damian, L, Piette, Y, Smith, V, Mera-Valera, A, Bachiller-Corral, J, Cabezas Rodriguez, I, Brandy-Garcia, A, Maurier, F, Perrin, J, Gonzalez-Moreno, J, Drott, U, Delbruck, C, Schwarting, A, Arrigoni, E, Sebastiani, G, Iuliano, A, Nannini, C, Quartuccio, L, Rodriguez Cambron, A, Blazquez Canamero, M, Villa Blanco, I, Cagnotto, G, Pesci, A, Luppi, F, Dei, G, Romero Bueno, F, Franceschini, F, Chiapparoli, I, Zanframundo, G, Lettieri, S, De Stefano, L, Cutolo, M, Mathieu, A, Piga, M, Prieto-Gonzalez, S, Moraes-Fontes, M, Fonseca, J, Jovani, V, Riccieri, V, Santaniello, A, Montfort, S, Bilocca, D, Erre, G, Bartoloni, E, Gerli, R, Monti, M, Lorenz, H, Sambataro, D, Bellando Randone, S, Schneider, U, Valenzuela, C, Lopez-Mejias, R, Cifrian, J, Mejia, M, Gonzalez Perez, M, Wendel, S, Fornaro, M, De Luca, G, Orsolini, G, Rossini, M, Dieude, P, Knitza, J, Castaneda, S, Voll, R, Rojas-Serrano, J, Valentini, A, Vancheri, C, Matucci-Cerinic, M, Feist, E, Codullo, V, Iannone, F, Distler, J, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Meloni F., Meyer A., Sambataro G., Belliato M., De Langhe E., Cavazzana I., Pipitone N., Triantafyllias K., Mosca M., Barsotti S., Zampogna G., Biglia A., Emmi G., De Visser M., Van Der Kooi A., Parronchi P., Hirschi S., da Silva J. A. P., Scire C. A., Furini F., Giannini M., Martinez Gonzalez O., Damian L., Piette Y., Smith V., Mera-Valera A., Bachiller-Corral J., Cabezas Rodriguez I., Brandy-Garcia A. M., Maurier F., Perrin J., Gonzalez-Moreno J., Drott U., Delbruck C., Schwarting A., Arrigoni E., Sebastiani G. D., Iuliano A., Nannini C., Quartuccio L., Rodriguez Cambron A. B., Blazquez Canamero M. A., Villa Blanco I., Cagnotto G., Pesci A., Luppi F., Dei G., Romero Bueno F. I., Franceschini F., Chiapparoli I., Zanframundo G., Lettieri S., De Stefano L., Cutolo M., Mathieu A., Piga M., Prieto-Gonzalez S., Moraes-Fontes M. F., Fonseca J. E., Jovani V., Riccieri V., Santaniello A., Montfort S., Bilocca D., Erre G. L., Bartoloni E., Gerli R., Monti M. C., Lorenz H. M., Sambataro D., Bellando Randone S., Schneider U., Valenzuela C., Lopez-Mejias R., Cifrian J., Mejia M., Gonzalez Perez M. -I., Wendel S., Fornaro M., De Luca G., Orsolini G., Rossini M., Dieude P., Knitza J., Castaneda S., Voll R. E., Rojas-Serrano J., Valentini A., Vancheri C., Matucci-Cerinic M., Feist E., Codullo V., Iannone F., Distler J. H., Montecucco C., and Gonzalez-Gay M. A.

Abstract

Objective To define the clinical spectrum time-course and prognosis of non-Asian patients positive for anti-MDA5 antibodies. Methods We conducted a multicentre, international, retrospective cohort study. Results 149 anti-MDA5 positive patients (median onset age 53 years, median disease duration 18 months), mainly females (100, 67%), were included. Dermatomyositis (64, 43%) and amyopathic dermatomyositis (47, 31%), were the main diagnosis; 15 patients (10%) were classified as interstitial pneumonia with autoimmune features (IPAF) and 7 (5%) as rheumatoid arthritis. The main clinical findings observed were myositis (84, 56%), interstitial lung disease (ILD) (108, 78%), skin lesions (111, 74%), and arthritis (76, 51%). The onset of these manifestations was not concomitant in 74 cases (50%). Of note, 32 (21.5%) patients were admitted to the intensive care unit for rapidly progressive-ILD, which occurred in median 2 months from lung involvement detection, in the majority of cases (28, 19%) despite previous immunosuppressive treatment. One-third of patients (47, 32% each) was ANA and anti-ENA antibodies negative and a similar percentage was anti-Ro52 kDa antibodies positive. Non-specific interstitial pneumonia (65, 60%), organising pneumonia (23, 21%), and usual interstitial pneumonia-like pattern (14, 13%) were the main ILD patterns observed. Twenty-six patients died (17%), 19 (13%) had a rapidly progressive-ILD. Conclusion The clinical spectrum of the anti-MDA5 antibodies-related disease is heterogeneous. Rapidly-progressive ILD deeply impacts the prognosis also in non-Asian patients, occurring early during the disease course. Anti-MDA5 antibody positivity should be considered even when baseline autoimmune screening is negative, anti-Ro52 kDa antibodies are positive, and radiology findings show a NSIP pattern.

Published
2022

10. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

Author

Agca, R, Heslinga, S C, Rollefstad, S, Heslinga, M, McInnes, I B, Peters, M J L, Kvien, T K, Dougados, M, Radner, H, Atzeni, F, Primdahl, J, Södergren, A, Wallberg Jonsson, S, van Rompay, J, Zabalan, C, Pedersen, T R, Jacobsson, L, de Vlam, K, Gonzalez-Gay, M A, Semb, A G, Kitas, G D, Smulders, Y M, Szekanecz, Z, Sattar, N, Symmons, D P M, and Nurmohamed, M T

Published
2017
Full Text
View/download PDF

11. TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY

Author

Prieto-Pena D, Loricera J, Castaneda S, Moriano C, Bernabeu P, Vela-Casasempere P, Narvaez J, Aldasoro V, Maiz O, Fernandez-Lopez C, Gonzalez M, Melero R, Villa-Blanco I, Gonzalez-Alvarez B, Solans-Laque R, Callejas-Rubio J, Fernandez-Diaz C, Romero E, Morillo S, Minguez M, Fernandez-Carballido C, De Miguel E, Sanchez-Martin J, Fernandez E, Melchor S, Salgado-Perez E, Bravo B, Romero-Yuste S, Galindez-Agirregoikoa E, Sivera F, Ferraz-Amaro I, Hidalgo C, Romero-Gomez C, Galisteo C, Moya P, Alvarez-Rivas N, Mendizabal J, Gonzalez J, De Dios J, Andreu J, de Pedro I, Revenga M, Valdivieso J, Rosa R, De la Morena I, Fernandez-Llanio N, Labrador E, Roman-Ivorra J, Ortiz-Sanjuan F, Garcia-Valle A, Gallego A, Iniguez C, Garrido-Punal N, De la Torre R, Lopez-Gonzalez R, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Feijoo M, Fernandez C, Rua-Figueroa I, Conesa A, Arija S, Gonzalez-Gay M, and Blanco R

Published
2022

13. Nailfold capillaroscopy characteristics of antisynthetase syndrome and possible clinical associations: Results of a multicenter international study

Author

Sebastiani, M, Triantafyllias, K, Manfredi, A, Gonzalez-Gay, M, Palmou-Fontana, N, Cassone, G, Drott, U, Delbruck, C, Rojas-Serrano, J, Bertolazzi, C, Nuno, L, Giannini, M, Iannone, F, Vicente, E, Castaneda, S, Selva-O'Callaghan, A, Araguas, E, Emmi, G, Iuliano, A, Bauhammer, J, Miehle, N, Parisi, S, Cavagna, L, Codullo, V, Montecucco, C, Lopez-Longo, F, Martinez-Barrio, J, Nieto-Gonzalez, J, Vichi, S, Confalonieri, M, Tomietto, P, Bergner, R, Sulli, A, Bonella, F, Furini, F, Scire, C, Bortoluzzi, A, Specker, C, Barsotti, S, Neri, R, Mosca, M, Caproni, M, Weinmann-Menke, J, Schwarting, A, Smith, V, Cutolo, M, Sebastiani M., Triantafyllias K., Manfredi A., Gonzalez-Gay M. A., Palmou-Fontana N., Cassone G., Drott U., Delbruck C., Rojas-Serrano J., Bertolazzi C., Nuno L., Giannini M., Iannone F., Vicente E. F., Castaneda S., Selva-O'Callaghan A., Araguas E. T., Emmi G., Iuliano A., Bauhammer J., Miehle N., Parisi S., Cavagna L., Codullo V., Montecucco C., Lopez-Longo F. J., Martinez-Barrio J., Nieto-Gonzalez J. C., Vichi S., Confalonieri M., Tomietto P., Bergner R., Sulli A., Bonella F., Furini F., Scire C. A., Bortoluzzi A., Specker C., Barsotti S., Neri R., Mosca M., Caproni M., Weinmann-Menke J., Schwarting A., Smith V., Cutolo M., Sebastiani, M, Triantafyllias, K, Manfredi, A, Gonzalez-Gay, M, Palmou-Fontana, N, Cassone, G, Drott, U, Delbruck, C, Rojas-Serrano, J, Bertolazzi, C, Nuno, L, Giannini, M, Iannone, F, Vicente, E, Castaneda, S, Selva-O'Callaghan, A, Araguas, E, Emmi, G, Iuliano, A, Bauhammer, J, Miehle, N, Parisi, S, Cavagna, L, Codullo, V, Montecucco, C, Lopez-Longo, F, Martinez-Barrio, J, Nieto-Gonzalez, J, Vichi, S, Confalonieri, M, Tomietto, P, Bergner, R, Sulli, A, Bonella, F, Furini, F, Scire, C, Bortoluzzi, A, Specker, C, Barsotti, S, Neri, R, Mosca, M, Caproni, M, Weinmann-Menke, J, Schwarting, A, Smith, V, Cutolo, M, Sebastiani M., Triantafyllias K., Manfredi A., Gonzalez-Gay M. A., Palmou-Fontana N., Cassone G., Drott U., Delbruck C., Rojas-Serrano J., Bertolazzi C., Nuno L., Giannini M., Iannone F., Vicente E. F., Castaneda S., Selva-O'Callaghan A., Araguas E. T., Emmi G., Iuliano A., Bauhammer J., Miehle N., Parisi S., Cavagna L., Codullo V., Montecucco C., Lopez-Longo F. J., Martinez-Barrio J., Nieto-Gonzalez J. C., Vichi S., Confalonieri M., Tomietto P., Bergner R., Sulli A., Bonella F., Furini F., Scire C. A., Bortoluzzi A., Specker C., Barsotti S., Neri R., Mosca M., Caproni M., Weinmann-Menke J., Schwarting A., Smith V., and Cutolo M.

Abstract

Objective. To describe nailfold videocapillaroscopy (NVC) features of patients with antisynthetase syndrome (AS) and to investigate possible correlations with clinical and serological features of the disease. Methods. We retrospectively analyzed NVC images of 190 patients with AS [females/males 3.63, mean age 49.7 ± 12.8 yrs, median disease duration 53.7 mos (interquartile range 82), 133 anti-Jo1 and 57 non-anti-Jo1-positive patients]. For each patient, we examined number of capillaries, giant capillaries, microhemorrhages, avascular areas, ramified capillaries, and the presence of systemic sclerosis (SSc)-like pattern. Finally, we correlated NVC features with clinical and serological findings of patients with AS. Concomitantly, a historical cohort of 75 patients with antinuclear antibody-negative primary Raynaud phenomenon (RP) and longterm followup was used as a control group (female/male ratio 4.13/1, mean age 53.9 ± 17.6 yrs) for NVC measures. Results. NVC abnormalities were observed in 62.1% of AS patients compared with 29.3% of primary RP group (p < 0.001). An SSc-like pattern was detected in 67 patients (35.3%) and it was associated with anti-Jo1 antibodies (p = 0.002) and also with a longer disease duration (p = 0.004). Interestingly, there was no significant correlation between the presence of SSc-like pattern and RP, and only 47% of patients with SSc-like pattern had RP. Conclusion. NVC abnormalities are commonly observed in AS, independently from the occurrence of RP. The presence of an SSc-like pattern could allow identification of a more defined AS subtype, and prospective studies could confirm the association with clinical and serological features of AS.

Published
2019

15. The fast progressor patient as an emerging clinical entity in patients with coronary atherosclerosis; exploratory study on possible molecular substrates

Author

Garcia Camarero, T, primary, De La Torre Hernandez, J M, additional, Remuzgo-Martinez, S, additional, Lera-Gomez, L, additional, Pulito-Cueto, V, additional, Genre, F, additional, Lopez-Mejias, R, additional, Perez-Fernandez, R, additional, Gonzalez-Gay, M A, additional, Veiga-Fernandez, G, additional, Sainz Laso, F, additional, and Lee Hwuang, D H, additional

Published
2021
Full Text
View/download PDF

18. CARDIOVASCULAR AND DISEASE RELATED FEATURES IN AXIAL SPONDYLITIS WITH AND WITHOUT CONCOMITANT PSORIASIS. A MULTICENTER STUDY WITH 882 PATIENTS

Author

Gonzalez-Mazon I, Rueda-Gotor J, Ferraz-Amaro I, Sanchez-Bilbao L, Genre F, Calvo-Rio V, Remuzgo-Martinez S, Pulito-Cueto V, Corrales A, Lera-Gomez L, Portilla V, Hernandez-Hernandez V, Quevedo-Abeledo J, Rodriguez-Lozano C, Lopez-Medina C, Pineda M, Castaneda S, Vicente-Rabaneda E, Fernandez-Carballido C, Martinez-Vidal M, Anino-Fernandez D, Plasencia D, Vivar M, Galindez E, Perez E, Fernandez-Diaz C, Blanco R, and Gonzalez-Gay M

Published
2021

19. HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE INDUCES RAPID IMPROVEMENT OF VISUAL ACUITY IN NON-INFECTIOUS UVEITIS OF DIFFERENT IMMUNE MEDIATED INFLAMMATORY DISEASES

Author

Vegas-Revenga N, Martin-Varillas J, Calvo-Rio V, Gonzalez-Mazon I, Sanchez-Bilbao L, Beltran E, Fonollosa A, Maiz-Alonso O, Blanco A, Cordero-Coma M, Ortego N, Torre-Salaberri I, Francisco F, Fernandez S, Esteban-Ortega M, Diaz-Llopis M, Canal J, Ventosa J, Demetrio-Pablo R, Dominguez L, Agudo-Bilbao M, Castaneda S, Ferraz-Amaro I, Gonzalez-Gay M, and Blanco R

Published
2021

20. Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases

Author

Sanchez-Bilbao L, Loricera J, Castaneda S, Moriano C, Narvaez J, Aldasoro V, Maiz O, Melero R, Villa J, Vela P, Romero-Yuste S, Callejas J, De Miguel E, Galindez-Agirregoikoa E, Sivera F, Fernandez-Lopez J, Galisteo C, Ferraz-Amaro I, Nieto J, de Dios J, Sanchez J, Fernandez E, de la Morena I, Moya P, Solans-Laque R, Andreu J, Revenga M, Labrador E, Garcia-Valle A, Gallego A, Iniguez C, Hidalgo C, Garrido-Punal N, Lopez-Gonzalez R, Roman-Ivorra J, Arija S, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Alvarez-Rivas N, Velloso-Feijoo M, Campos-Fernandez C, Rua-Figueroa I, Conesa A, Salgado E, Gonzalez-Gay M, and Blanco R

Published
2021

21. Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice

Author

Sanchez-Bilbao L, Loricera J, Acha J, Moriano C, Narvaez J, Aldasoro V, Maiz O, Melero R, Villa J, Vela P, Romero-Yuste S, Callejas J, De Miguel E, Galindez-Agirregoikoa E, Sivera F, Fernandez-Lopez J, Galisteo C, Ferraz-Amaro I, Nieto J, de Dios J, Sanchez J, Fernandez E, de la Morena I, Moya P, Solans-Laque R, Andreu J, Revenga M, Pinillos V, Garcia-Valle A, Gallego A, Iniguez C, Hidalgo C, Garrido-Punal N, Lopez-Gonzalez R, Roman-Ivorra J, Arija S, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Alvarez-Rivas N, Velloso-Feijoo M, Campos-Fernandez C, Rua-Figueroa I, Conesa A, Salgado E, Gonzalez-Gay M, and Blanco R

Published
2021

22. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study

Author

Gracia J, Sanchez-Piedra C, Manero J, Ruiz-Lucea M, Lopez-Vives L, Bohorquez C, Martinez-Barrio J, Bonilla G, Vela P, Garcia-Villanueva M, Navio-Marco M, Pavia M, Galindo M, Erausquin C, Gonzalez-Gay M, Rua-Figueroa I, Pego-Reigosa J, Castrejon I, Sanchez-Costa J, Gonzalez-Davila E, Diaz-Gonzalez F, and COVIDSER Study Grp

Subjects
biological therapy, immune system diseases, COVID-19, outcome assessment, health care
Abstract

Objectives To analyse the effect of targeted therapies, either biological (b) disease-modifying antirheumatic drugs (DMARDs), targeted synthetic (ts) DMARDs and other factors (demographics, comorbidities or COVID-19 symptoms) on the risk of COVID-19 related hospitalisation in patients with inflammatory rheumatic diseases. Methods The COVIDSER study is an observational cohort including 7782 patients with inflammatory rheumatic diseases. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Antirheumatic medication taken immediately prior to infection, demographic characteristics, rheumatic disease diagnosis, comorbidities and COVID-19 symptoms were analysed. Results A total of 426 cases of symptomatic COVID-19 from 1 March 2020 to 13 April 2021 were included in the analyses: 106 (24.9%) were hospitalised and 19 (4.4%) died. In multivariate-adjusted models, bDMARDs and tsDMARDs in combination were not associated with hospitalisation compared with conventional synthetic DMARDs (OR 0.55, 95% CI 0.24 to 1.25 of b/tsDMARDs, p=0.15). Tumour necrosis factor inhibitors (TNF-i) were associated with a reduced likelihood of hospitalisation (OR 0.32, 95% CI 0.12 to 0.82, p=0.018), whereas rituximab showed a tendency to an increased risk of hospitalisation (OR 4.85, 95% CI 0.86 to 27.2). Glucocorticoid use was not associated with hospitalisation (OR 1.69, 95% CI 0.81 to 3.55). A mix of sociodemographic factors, comorbidities and COVID-19 symptoms contribute to patients' hospitalisation. Conclusions The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role.

Published
2021

25. RAPID IMPROVEMENT IN CYSTOID MACULAR EDEMA WITH HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE IN NON-INFECTIOUS UVEITIS OF DIFFERENT IMMUNE MEDIATED INFLAMMATORY DISEASES

Author

Vegas-Revenga N, Martin-Varillas J, Calvo-Rio V, Gonzalez-Mazon I, Sanchez-Bilbao L, Beltran E, Fonollosa A, Maiz-Alonso O, Blanco A, Cordero-Coma M, Ortego N, Torre-Salaberri I, Francisco F, Fernandez S, Esteban-Ortega M, Diaz-Llopis M, Canal J, Ventosa J, Demetrio-Pablo R, Dominguez L, Agudo-Bilbao M, Castaneda S, Ferraz-Amaro I, Gonzalez-Gay M, and Blanco R

Published
2021

26. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients

Author

Calderon-Goercke M, Castaneda S, Aldasoro V, Villa I, Moriano C, Romero-Yuste S, Narvaez J, Gomez-Arango C, Perez-Pampin E, Melero R, Becerra-Fernandez E, Revenga M, Alvarez-Rivas N, Galisteo C, Sivera F, De Miguel E, Prieto-Pena D, Gonzalez-Gay M, Hernandez J, Blanco R, and Tocilizumab Giant Cell Arteritis S

Subjects
Immunosuppressive drugs, Tocilizumab, Cranial arteritis, Monotherapy, Giant cell arteritis
Abstract

Objective: To compare the efficacy and safety of TCZ in monotherapy (TCZ(MONO)) vs. combined with conventional immunosuppressive drugs (TCZ(COMBO)) in Giant Cell Arteritis (GCA) in a clinical practice scenario. Methods: Multicenter study of 134 patients with refractory GCA. Patients on TCZ(MONO) (n = 82) were compared with those on TCZ(COMBO) (n = 52). Drugs were methotrexate (MTX) (n = 48), azathioprine (n = 3), and lefluno-mide (n = 1). The main outcomes were: prolonged remission (normalization of clinical and laboratory parameters for at least 6 months) and the number of relapses. Results: Patients on TCZ(COMBO) were younger (68.8 +/- 8.0 vs 71.2 +/- 9.0 years; p = 0.04), with a trend to a longer GCA duration (median [IQR],18.5 [6.25-34.0] vs. 13.0 [7.75-33.5] months; p = 0.333), higher C-reactive protein (CRP) levels (2.1[1-4.7] vs 1.2 [0.2-2.4] mg/dL; p = 0.003), and more prevalence of extra-cranial large vessel vasculitis (LVV) (57% vs. 34.1%; p = 0.007). In both groups, rapid and sustained improvement was observed. Despite the longer GCA duration, and the higher CRP levels and prevalence of LVV in the TCZ(COMBO), the improvement was similar in both groups at 12 months. Moreover, in the TCZ(COMBO) group, prolonged remission was significantly higher at 12-month. Relapses and serious adverse events were similar in both groups. Conclusion: In clinical practice, TCZ in monotherapy or combined with conventional immunosuppressive agents is effective and safe in patients with GCA. Nevertheless, the addition of immunosuppressive drugs, usually MTX, seems to allow a higher rate of prolonged remission, even in patients with a longer GCA duration, more extra-cranial LVV involvement, and higher acute-phase reactants. (C) 2021 Elsevier Inc. All rights reserved.

Published
2021

27. Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review

Author

Prieto-Pena D, Bernabeu P, Vela P, Narvaez J, Fernandez-Lopez J, Freire-Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Rubio J, Ortego N, Fernandez-Diaz C, Rubio E, Garcia-Morillo S, Minguez M, Fernandez-Carballido C, de Miguel E, Melchor S, Salgado E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Ortiz-Sanjuan F, de Pedro I, Alonso-Valdivielso J, Perez-Sanchez L, Roldan R, Fernandez-Llanio N, de la Torre R, Suarez S, Cabrera M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R

Subjects
Takayasu's arteritis, cDMARDs, biological therapy, Caucasian, Tocilizumab
Abstract

Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ(MONO)) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ(COMBO)) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ(MONO) and 31 (57.4%) on TCZ(COMBO): MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ(COMBO) were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

Published
2021

28. COMPARATIVE STUDY ON ANTI-TNF VS TOCILIZUMAB FOR TREATMENT OF REFRACTORY UVEITIC CYSTOID MACULAR EDEMA DUE TO BEHCET'S DISEASE. MULTICENTER STUDY OF 49 PATIENTS

Author

Atienza-Mateo B, Ferraz-Amaro I, Catalan E, Adan A, Garfella M, Martinez-Costa L, Coma M, Diaz-Llopis M, Herreras J, Blanco A, Torre I, Diaz-Valle D, Atanes-Sandoval A, Hernandez F, Insua S, Sanchez J, Almodovar R, Ruiz-Moreno O, Martinez M, Nolla J, Martin-Varillas J, Calvo-Rio V, Prieto-Pena D, Gonzalez-Gay M, and Blanco R

Published
2021

29. ROLE OF VASPIN IN ATHEROSCLEROTIC DISEASE AND CARDIOVASCULAR RISK IN AXIAL SPONDYLOARTHRITIS

Author

Rueda-Gotor J, Lopez-Mejias R, Remuzgo-Martinez S, Cueto V, Corrales A, Lera-Gomez L, Portilla V, Gonzalez-Mazon I, Blanco R, Exposito R, Mata C, Llorca J, Hernandez-Hernandez V, Rodriguez-Lozano C, Puerto N, Castro R, Castaneda N, Fernandez-Carballido C, Martinez-Vidal M, Castro-Corredor D, Anino-Fernandez J, Peiteado D, Plasencia C, Galindez E, Vivar M, Gualillo O, Quevedo-Abeledo J, Castaneda S, Ferraz-Amaro I, Gonzalez-Gay M, and Genre F

Published
2021

30. TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS

Author

Prieto-Pena D, Bernabeu P, Vela-Casasempere P, Narvaez J, Fernandez-Lopez C, Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Callejas-Rubio J, Ortego N, Fernandez-Diaz C, Romero E, Morillo S, Minguez M, Fernandez-Carballido C, De Miguel E, Melchor S, Salgado-Perez E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Arija S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Sanjuan F, de Pedro I, Valdivieso J, Laura P, Rosa R, Fernandez-Llanio N, de la Torre R, Suarez S, Montesa M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R

Published
2021

31. COMPARISON OF CAROTID SUBCLINICAL ATHEROSCLEROSIS AND STRUCTURAL DAMAGE IN AXIAL SPONDYLITIS WITH AND WITHOUT CONCOMITANT INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY WITH 886 PATIENTS.. A MULTICENTER STUDY WITH 886 PATIENTS

Author

Gonzalez-Mazon I, Rueda-Gotor J, Ferraz-Amaro I, Sanchez-Bilbao L, Genre F, Calvo-Rio V, Remuzgo-Martinez S, Pulito-Cueto V, Corrales A, Lera-Gomez L, Portilla V, Hernandez-Hernandez V, Quevedo-Abeledo J, Rodriguez-Lozano C, Lopez-Medina C, Pineda M, Castaneda S, Garcia-Castaneda N, Fernandez-Carballido C, Martinez-Vidal M, Castro-Corredor D, Anino-Fernandez J, Peiteado D, Plasencia C, Vivar M, Galindez E, Perez E, Fernandez-Diaz C, Blanco R, and Gonzalez-Gay M

Published
2021

32. COMPARISON OF CAROTID SUBCLINICAL ATHEROSCLEROSIS AND STRUCTURAL DAMAGE IN AXIAL SPONDYLITIS WITH AND WITHOUT CONCOMITANT ANTERIOR UVEITIS. A MULTICENTER STUDY WITH 886 PATIENTS

Author

Gonzalez-Mazon I, Rueda-Gotor J, Ferraz-Amaro I, Sanchez-Bilbao L, Genre F, Calvo-Rio V, Remuzgo-Martinez S, Pulito-Cueto V, Corrales A, Lera-Gomez L, Portilla V, Hernandez-Hernandez V, Quevedo-Abeledo J, Rodriguez-Lozano C, Lopez-Medina C, Pineda M, Castaneda S, Vicente-Rabaneda E, Fernandez-Carballido C, Martinez-Vidal M, Castro-Corredor D, Anino-Fernandez J, Peiteado D, Vivar M, Galindez E, Perez E, Demetrio-Pablo R, Fernandez-Diaz C, Blanco R, and Gonzalez-Gay M

Published
2021

33. Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry

Author

De Miguel, E, Sanchez-Costa, JT, Narvaez, J, Gonzalez-Gay, M, Garrido-Punal, N, Estrada-Alarcon, PV, Hernandez-Rodriguez, I, Fernandez-Fernandez, E, Silva-Diaz, MT, Valero-Jaimes, JA, Gonzalez-Fernandez, I, Sanchez, J, Lluch, J, Galindez-Agirregoikoa, E, Mendizabal-Mateos, J, Rodriguez, LR, Garcia, JL, Munoz, A, Castaneda, S, Moya, P, Moran-Alvarez, P, Navarro-Angeles, VA, Calvet-Fontova, J, Casafont, I, Ortiz-Sanjuan, F, Labrada-Arrabal, S, Campos-Fernandez, C, Alcalde-Villar, M, Juan-Mas, A, and Blanco, R

Published
2021

34. Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association

Author

Sebastiani, M, Luppi, F, Sambataro, G, Castillo Villegas, D, Cerri, S, Tomietto, P, Cassone, G, Bocchino, M, Atienza-Mateo, B, Cameli, P, Moya Alvarado, P, Faverio, P, Bargagli, E, Vancheri, C, Gonzalez-Gay, M, Clini, E, Salvarani, C, Manfredi, A, Sebastiani, Marco, Luppi, Fabrizio, Sambataro, Gianluca, Castillo Villegas, Diego, Cerri, Stefania, Tomietto, Paola, Cassone, Giulia, Bocchino, Marialuisa, Atienza-Mateo, Belen, Cameli, Paolo, Moya Alvarado, Patricia, Faverio, Paola, Bargagli, Elena, Vancheri, Carlo, Gonzalez-Gay, Miguel A, Clini, Enrico, Salvarani, Carlo, Manfredi, Andreina, Sebastiani, M, Luppi, F, Sambataro, G, Castillo Villegas, D, Cerri, S, Tomietto, P, Cassone, G, Bocchino, M, Atienza-Mateo, B, Cameli, P, Moya Alvarado, P, Faverio, P, Bargagli, E, Vancheri, C, Gonzalez-Gay, M, Clini, E, Salvarani, C, Manfredi, A, Sebastiani, Marco, Luppi, Fabrizio, Sambataro, Gianluca, Castillo Villegas, Diego, Cerri, Stefania, Tomietto, Paola, Cassone, Giulia, Bocchino, Marialuisa, Atienza-Mateo, Belen, Cameli, Paolo, Moya Alvarado, Patricia, Faverio, Paola, Bargagli, Elena, Vancheri, Carlo, Gonzalez-Gay, Miguel A, Clini, Enrico, Salvarani, Carlo, and Manfredi, Andreina

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA), mainly anti-myeloperoxidase (MPO) antibodies, have been frequently identified in patients with idiopathic pulmonary fibrosis (IPF). However, their role remains unclear, and only 7-23% of these patients develops clinically overt vasculitis. We aimed to investigate the clinical, serological, and radiological features and prognosis of anti-MPO-positive interstitial lung disease (ILD) patients. Fifty-eight consecutive patients firstly referred for idiopathic interstitial pneumonia and showing serological positivity of anti-MPO antibodies were retrospectively enrolled. For each patient, clinical data, lung function testing, chest high-resolution computed tomography (HRCT) pattern, and survival were recorded. Thirteen patients developed a rheumatic disease during a median follow-up of 39 months. Usual interstitial pneumonia (UIP) was the most frequent ILD pattern, significantly influencing the patients' survival. In fact, while the 52-week survival of the overall population was 71.4 ± 7.5%, significantly higher than IPF, survivals of anti-MPO patients with UIP pattern and IPF were similar. Forced vital capacity and diffusion lung capacity for CO significantly declined in 37.7 and 41.5% of cases, respectively, while disease progression at chest HRCT was observed in 45.2%. A careful clinical history and evaluation should always be performed in ILD patients with anti-MPO antibodies to quickly identify patients who are developing a systemic rheumatic disease.

Published
2021

35. Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up

Author

Martin-Martinez M, Castaneda S, Sanchez-Alonso F, Garcia-Gomez C, Juanatey C, Belmonte-Lopez M, Tornero-Molina J, Santos-Rey J, Sanchez-Gonzalez C, Moreno E, Moreno-Gil M, Cobo-Ibanez T, Pinto-Tasende J, Babio-Herraez J, Bonilla G, Juan-Mas A, Manero-Ruiz F, Romera-Baures M, Bachiller-Corral J, Chamizo-Carmona E, Calvo-Catalan J, Sanmarti R, Erausquin-Arruabarrena C, Garcia-Vicuna R, Barbadillo C, Ros-Exposito S, Turrion A, Gonzalez-Fernandez M, Senabre J, Martinez-Pardo S, Ruibal-Escribano A, Giner-Serret E, Berzosa-Sola E, Martinez-Barrio J, Pagan E, Enriqueta-Peiro M, Bustabad-Reyes S, Erra-Duran A, Alvarez B, Valenciano A, Rivera-Redondo J, Ramos M, Montero S, Morcillo-Valle M, Navio M, Galindo-Izquierdo M, Riera-Soler M, Fiter J, Llorca J, and Gonzalez-Gay M

Published
2020

36. APREMILAST IN MONOTHERAPY OR COMBINED IN NON-ULCER MANIFESTATIONS OF BEHCET'S DISEASE. NATIONAL MULTICENTER STUDY OF 34 REFRACTORY CASES OF CLINICAL PRACTICE

Author

Morant, A, Mateo, B, Loricera, J, del Rio, V, Martin-Varillas, J, Espinosa, G, Grana, J, Moriano, C, Sandoval, T, Martinez, M, Diez, E, Garcia-Armario, M, Martinez, E, Castellvi, I, Alvarado, P, Sivera, F, Calvo, J, De la Morena, I, Sanjuan, F, Ivorra, J, Gomez, A, Olive, A, Diez, C, Alegre, J, Ybanez-Garcia, D, Martinez-Ferrer, A, Narvaez, J, Figueras, I, Turrion, A, Romero-Yuste, S, Trenor, P, Ojeda, S, Gonzalez-Gay, M, and Blanco, R

Published
2020

37. Variants of PBEF predispose to systemic sclerosis and pulmonary arterial hypertension development

Author

Mayes M, Coenen MJH, Airò P, Gonzalez-Gay M A, Ortego-Centeno N, Carreira P, Fonollosa V, Simeon C P, Scorza R, Kiener H, Riemekasten G, Fonseca C, Denton C, Hunzelman N, Worthington J, Hesselstrand R, Herrick A, Brouwer C, Rueda B, Geurts-van Bon L, Niederer F, Beretta L, Vonk M C, Broen JCA, Gourh P, Kyburz D, Arnett F C, Martin J, and Radstake TRDJ

Subjects
Medicine
Published
2010
Full Text
View/download PDF

38. Polymorphisms in the interleukin 4, interleukin 13 and corresponding receptor genes are not associated with Systemic Sclerosis and do not influence gene expression

Author

Aliprantis A, Coenen MJH, Airò P, Gonzalez-Gay M A, Ortego-Centeno N, Carreira P, Fonollosa V, Scorza R, Simeon C P, Kiener H, Riemekasten G, Hunzelmann N, Worthington J, Herrick A, Rueda B, Beretta L, Vonk M C, Dieude P, Broen JCA, Martin J, Allanore Y, and Radstake TRDJ

Subjects
Medicine
Published
2010
Full Text
View/download PDF

41. A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators

Author

Broen, J. C. A., Bossini-Castillo, L., van Bon, L., Vonk, M. C., Knaapen, H., Beretta, L., Rueda, B., Hesselstrand, R., Herrick, A., Worthington, J., Hunzelman, N., Denton, C. P., Fonseca, C., Riemekasten, G., Kiener, H. P., Scorza, R., Simeón, C. P., Ortego-Centeno, N., Gonzalez-Gay, M. A., Airò, P., Coenen, M. J. H., Martín, J., and Radstake, T. R. D. J.

Published
2012
Full Text
View/download PDF

42. Polymorphisms in the interleukin 4, interleukin 13 and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression

Author

Broen, J C A, Dieude, P, Vonk, M C, Beretta, L, Rueda, B, Herrick, A, Worthington, J, Hunzelmann, N, Riemekasten, G, Kiener, H, Scorza, R, Simeon, C P, Fonollosa, V, Carreira, P, Ortego-Centeno, N, Gonzalez-Gay, M A, Airoʼ, P, Coenen, M J H, Aliprantis, A, Martin, J, Allanore, Y, and Radstake, T R D J

Published
2011
Full Text
View/download PDF

43. Variants of PBEF predispose to systemic sclerosis and pulmonary arterial hypertension development

Author

Broen, J C A, Gourh, P, Vonk, M C, Beretta, L, Niederer, F, Rueda, B, Geurts-van Bon, L, Brouwer, C, Hesselstrand, R, Herrick, A, Worthington, J, Hunzelman, N, Fonseca, Denton C, Riemekasten, G, Kiener, H, Scorza, R, Simeon, C P, Fonollosa, V, Carreira, P, Ortego-Centeno, N, Gonzalez-Gay, M A, Airoʼ, P, Coenen, M J H, Mayes, M, Kyburz, D, Arnett, F C, Martin, J, and Radstake, T R D J

Published
2011
Full Text
View/download PDF

45. Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group

Author

Cavagna, L, Nuno, L, Scire, C, Govoni, M, Longo, F, Franceschini, F, Neri, R, Castaneda, S, Sifuentes Giraldo, W, Caporali, R, Iannone, F, Fusaro, E, Paolazzi, G, Pellerito, R, Schwarting, A, Saketkoo, L, Ortego-Centeno, N, Quartuccio, L, Bartoloni, E, Specker, C, Pina Murcia, T, La Corte, R, Furini, F, Foschi, V, Bachiller Corral, J, Airo, P, Cavazzana, I, Martinez-Barrio, J, Hinojosa, M, Giannini, M, Barsotti, S, Menke, J, Triantafyllias, K, Vitetta, R, Russo, A, Bogliolo, L, Bajocchi, G, Bravi, E, Barausse, G, Bortolotti, R, Selmi, C, Parisi, S, Salaffi, F, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Nuno L., Scire C. A., Govoni M., Longo F. J. L., Franceschini F., Neri R., Castaneda S., Sifuentes Giraldo W. A., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L. A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Pina Murcia T., La Corte R., Furini F., Foschi V., Bachiller Corral J., Airo P., Cavazzana I., Martinez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bogliolo L., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Salaffi F., Montecucco C., Gonzalez-Gay M. A., Cavagna, L, Nuno, L, Scire, C, Govoni, M, Longo, F, Franceschini, F, Neri, R, Castaneda, S, Sifuentes Giraldo, W, Caporali, R, Iannone, F, Fusaro, E, Paolazzi, G, Pellerito, R, Schwarting, A, Saketkoo, L, Ortego-Centeno, N, Quartuccio, L, Bartoloni, E, Specker, C, Pina Murcia, T, La Corte, R, Furini, F, Foschi, V, Bachiller Corral, J, Airo, P, Cavazzana, I, Martinez-Barrio, J, Hinojosa, M, Giannini, M, Barsotti, S, Menke, J, Triantafyllias, K, Vitetta, R, Russo, A, Bogliolo, L, Bajocchi, G, Bravi, E, Barausse, G, Bortolotti, R, Selmi, C, Parisi, S, Salaffi, F, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Nuno L., Scire C. A., Govoni M., Longo F. J. L., Franceschini F., Neri R., Castaneda S., Sifuentes Giraldo W. A., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L. A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Pina Murcia T., La Corte R., Furini F., Foschi V., Bachiller Corral J., Airo P., Cavazzana I., Martinez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bogliolo L., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Salaffi F., Montecucco C., and Gonzalez-Gay M. A.

Abstract

Anti-Jo-1 is the most frequently detectable antibody in the antisynthetase syndrome (ASSD), an autoimmune disease characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). Recently, we organized an international collaborative group called American and European NEtwork of Antisynthetase Syndrome (AENEAS) for the study of this rare and fascinating disease. The group collected and published one of the largest series of ASSD patients ever described and with one of the longer follow-up ever reported. The number of participating centers is steadily increasing, as well as the available cohort. In the first paper, we showed that arthritis, myositis, and ILD may be frequently the only feature at disease onset, raising problems to reach a correct diagnosis of this syndrome. Nevertheless, we first observed that the ex novo appearance of further manifestations is common during the follow-up, strengthening the importance of a correct diagnosis. In our cohort, the 24 % of the 243 patients up to now collected had isolated arthritis as a presenting feature. These patients represent the most intriguing group in terms of differential diagnosis and clinical time course. Furthermore, data on this aspect are scanty, the reason that lead us to evaluate these aspects in our cohort of patients, reviewing also available literature. In fact, the most relevant aspect is that ASSD is rarely suspected in this setting of patients, in particular in case of poliarticular involvement, positive rheumatoid factor (RF), or anti-cyclic citrullinated peptide antibodies (ACPA) or evidence of joint erosions at plain radiographs. These findings were not rare in our cohort, and they have been also described in other series. Furthermore, manifestations such as Raynaud’s phenomenon, mechanic’s hands, and fever that may lead to the suspect of ASSD are observed only in a third of cases. If we consider the high rate of clinical picture progression in these patients, we fee

Published
2017

46. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study

Author

Bartoloni, E, Gonzalez-Gay, M, Scire, C, Castaneda, S, Gerli, R, Lopez-Longo, F, Martinez-Barrio, J, Govoni, M, Furini, F, Pina, T, Iannone, F, Giannini, M, Nuno, L, Quartuccio, L, Ortego-Centeno, N, Alunno, A, Specker, C, Montecucco, C, Triantafyllias, K, Balduzzi, S, Sifuentes-Giraldo, W, Paolazzi, G, Bravi, E, Schwarting, A, Pellerito, R, Russo, A, Selmi, C, Saketkoo, L, Fusaro, E, Parisi, S, Pipitone, N, Franceschini, F, Cavazzana, I, Neri, R, Barsotti, S, Codullo, V, Cavagna, L, Bartoloni E., Gonzalez-Gay M. A., Scire CA., Castaneda S., Gerli R., Lopez-Longo F. J., Martinez-Barrio J., Govoni M., Furini F., Pina T., Iannone F., Giannini M., Nuno L., Quartuccio L., Ortego-Centeno N., Alunno A., Specker C., Montecucco C., Triantafyllias K., Balduzzi S., Sifuentes-Giraldo W. A., Paolazzi G., Bravi E., Schwarting A., Pellerito R., Russo A., Selmi C., Saketkoo L. -A., Fusaro E., Parisi S., Pipitone N., Franceschini F., Cavazzana I., Neri R., Barsotti S., Codullo V., Cavagna L., Bartoloni, E, Gonzalez-Gay, M, Scire, C, Castaneda, S, Gerli, R, Lopez-Longo, F, Martinez-Barrio, J, Govoni, M, Furini, F, Pina, T, Iannone, F, Giannini, M, Nuno, L, Quartuccio, L, Ortego-Centeno, N, Alunno, A, Specker, C, Montecucco, C, Triantafyllias, K, Balduzzi, S, Sifuentes-Giraldo, W, Paolazzi, G, Bravi, E, Schwarting, A, Pellerito, R, Russo, A, Selmi, C, Saketkoo, L, Fusaro, E, Parisi, S, Pipitone, N, Franceschini, F, Cavazzana, I, Neri, R, Barsotti, S, Codullo, V, Cavagna, L, Bartoloni E., Gonzalez-Gay M. A., Scire CA., Castaneda S., Gerli R., Lopez-Longo F. J., Martinez-Barrio J., Govoni M., Furini F., Pina T., Iannone F., Giannini M., Nuno L., Quartuccio L., Ortego-Centeno N., Alunno A., Specker C., Montecucco C., Triantafyllias K., Balduzzi S., Sifuentes-Giraldo W. A., Paolazzi G., Bravi E., Schwarting A., Pellerito R., Russo A., Selmi C., Saketkoo L. -A., Fusaro E., Parisi S., Pipitone N., Franceschini F., Cavazzana I., Neri R., Barsotti S., Codullo V., and Cavagna L.

Abstract

Objective Arthritis, myositis and interstitial lung disease (ILD) constitute the classic clinical triad of anti-synthetase syndrome (ASSD). These patients experience other accompanying features, such as Raynaud's phenomenon, fever or mechanic's hands. Most ASSD patients develop the complete triad during the follow-up. In the present study we aimed to determine whether the subsequent appearance of accompanying features may suggest the development of triad findings lacking at the onset in anti-Jo1 positive ASSD patients. Methods Anti-Jo1 positive patients presenting with incomplete ASSD (no > 2 classic triad features) were assessed. Clinical characteristics and clusters of disease manifestations were retrospectively collected and analyzed in a large international multicenter cohort of ASSD patients. Results 165 patients (123 women) with incomplete ASSD were identified. Ninety-five patients (57.5%) developed new classic triad manifestations after 15 months median (IQR 9–51) and 40 (24%) developed new accompanying features after 19 months median (IQR 6–56) from disease onset. During the follow-up, the ex-novo occurrence of triad features was observed in 32 out of 40 patients (80%) with new accompanying findings and in 63 out of 125 patients (50.5%) without new accompanying findings (p = 0.002). In patients with at least one new accompanying feature the odds ratio for the occurrence of new triad manifestations was 3.94 with respect to patients not developing ex-novo accompanying findings (95% CI 1.68–9.21, p = 0.002). Conclusion Anti-Jo1 ASSD patients with incomplete forms at disease onset are at high risk for the subsequent occurrence of lacking classic triad findings. Although all ASSD patients should be carefully assessed for the occurrence of new triad features, a closer follow-up should be considered in the subgroup of patients developing ex novo accompanying findings. These patients, indeed, have near four-fold increased risk f

Published
2017

47. A large multicentre analysis of CTGF −945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype

Author

Rueda, B, Simeon, C, Hesselstrand, R, Herrick, A, Worthington, J, Ortego-Centeno, N, Riemekasten, G, Fonollosa, V, Vonk, M C, van den Hoogen, F H J, Sanchez-Román, J, Aguirre-Zamorano, M A, García-Portales, R, Pros, A, Camps, M T, Gonzalez-Gay, M A, Gonzalez-Escribano, M F, Coenen, M J, Lambert, N, Nelson, J L, Radstake, T R D J, and Martin, J

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results